Regeneron to highlight progress across its differentiated oncology portfolio and pipeline at wclc and esmo

At wclc, five-year survival data to be presented on libtayo (pd-1 inhibitor) first-line monotherapy in advanced non-small cell lung cancer

REGN Ratings Summary

REGN Quant Ranking